DAY THREE - Stream B: Stem Cells for Drug Discovery

last modified: 22 May '12

Please enable javascript to see more information on speakers

9am

Chairman’s opening remarks

Ming Hao Zheng

Professor Ming H Zheng (MD, PhD, FRCPath, FRCPA) is the Associate Dean of the Faculty of Medicine, Dentistry and Health Sciences at the University of Western Australia, and the Director of Research at the Centre for Translational Orthopaedic...

more..

› Ming Hao Zheng, Winthrop Professor, Associate Dean, University of Western Australia

9.10am

Stratified medicine in a dish using human induced pluripotent stem cells

Ludovic Vallier

Ludovic Vallier is a MRC senior-non clinical fellow affiliated to the Department of Surgery Cambridge University, principal investigator in the Anne McLaren laboratory for Regenerative Medicine and director of the Cambridge Biomedical Research...

more..

Large scale derivation of human Induced Pluripotent Stem Cells for personalised medicine.
Modelling metabolic disorders using hIPSC for drug and toxicology screen screening.
Variability inter and intra hIPSC lines is relevant for stratified medicine.
Genomic and epigenomic stability of hIPSC lines as a tool for understanding diseases mechanisms

› Ludovic Vallier, Senior Non-Clinical MRC Fellow, University of Cambridge

INDUSTRIALISING STEM CELLS FOR DISCOVERY

9.40am

Producing high quality cells for rapid drug discovery and clinical application

Glyn Stacey

Glyn Stacey has a background in public health and cancer research and has worked on the development of cell substrates for manufacture of biological medicines. He is currently Head of Division of Cell Biology and Imaging and Director for the UK Stem ...

more..

Delivery of stem cell lines for clinical application
What are the challenges to suppliers in maintaining pluripotency, delivering relevant stem cell type and meeting increased demand?
What is the researcher’s perspective going forward as the requirement for stem cells in drug discovery increase and expectations over quality rise?
Importance of high quality research materials to drive translational research

› Glyn Stacey, Director, U.K. Stem Cell Bank, Head of Cell Biology and Imaging, UK, National Institute for Biological Standards and Control,

SAFETY FIRST TO SUCCEED IN DRUG DISCOVERY

10.10am

Pharma perspective on safety concerns as stem cells as therapeutic agents grow

Michaela Sharpe

Michaela Sharpe is currently head of the Stem Cell Safety Group at Pfizer and has designed and implemented the safety programmes for Pfizer’s lead stem cell based therapy products. She has over 10 years experience in nonclinical development in the...

more..

How to develop and implement innovative safety strategies?
How can disease models be harnessed in pivotal safety studies?
What are the regulatory requirements for drug safety data in a stem cell context?

› Michaela Sharpe, Head Stem Cell Safety Group, Pfizer

10.40am

Morning refreshments

CANCER STEM CELLS AS THERAPEUTIC TARGETS

11.10am

The promise of identifying and targeting cancer stem cells to discover treatments

Davide Danovi

Davide had his MD and then PhD at the European Institute of Oncology in Milan, Italy. He then joined the laboratory of Austin Smith at the University of Cambridge, UK where he has taken forward pioneering work of Steve Pollard on brain tumour stem...

more..

Targeting critical pathways involved in cancer stem cell biology
Development of poignant in vitro and in vivo assays for drug discovery purposes
Characterisation of new therapeutic agents targeting vital cancer stem cell pathways

› Davide Danovi, Research Associate, Samantha Dickson Brain Cancer Unit, Cancer Institute, University College London

11.35am

Advancing cancer stem cell therapeutic programmes

Dominique Bonnet

After obtaining a PhD degree in the University of Paris VII in 1993, Dr D Bonnet joined the group of Prof. John Dick’s laboratory in Toronto, Canada where she stayed as a research fellow for four years. She worked there on establishing an in vivo...

more..

How can pure populations of cancer stem cells be isolated for individual cancer types?
Understanding the genetic complexities of cancer stem cells and identifying universal consistencies for all cancer types?
How might new drugs target and eliminate cancer stem cells and the source of tumours?
How might this be used with current cancer treatment?

› Dominique Bonnet, Researcher, Cancer Research UK

MANAGING THE FUTURE EXPECTATIONS OF STEMS CELLS IN DRUG DISCOVERY

12pm

Possible use of MSCs and iHep-like cells in drug discovery

Andreas Nuessler

Prof. Andreas K. Nussler is a German native. He studied Pharmacy and human biology in Germany and France. He received his PhD from University Paris VI, France in 1991. From 1991 to 1994 he worked as Research Assistant Prof. at Pittsburgh Medical...

more..

How to direct the differentiation from mesenchymal stem cell to a hepatocyte?
What are the advantages compared to classical iPS model?
New approaches of direct transdifferentiation of fibroblasts into hepatocytes-like cells
What does the future hold for reprogramming human cells and reducing the need for liver transplants?

› Andreas Nuessler, Head R&D, Eberhard-Karls University Tubingen

STEM CELL-BASED COLLABORATIONS

12.25pm

Securing the funds and establishing the collaborations to start up successfully for a cell therapy

Sloan Fellow Alain Vertes

Dr Alain Vertès is a Sloan Fellow from London Business School and was Global Alliance Director at Roche in the Pharma Partnering group, identifying strategic needs, finding, implementing and managing partnerships from licensing to M&As. He...

more..